Incorporating the TyG index into CRC screening protocols enables healthcare providers to identify high-risk individuals who could potentially benefit from targeted interventions, such as lifestyle modifications and pharmacological treatments to improve insulin sensitivity. The gene discussed is INS; the disease is colorectal carcinoma.